PDF(Pubmed)
Abstract：
UNASSIGNED: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS).
UNASSIGNED: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as <60 years of age (n=610), and those aged ≥60 years (n=201) were recorded as elderly patients. Demographic, clinical, and laboratory characteristics, along with disease activity markers and other follow-up parameters, as well as current and prior treatments, were electronically recorded during each visit using open-source software.
UNASSIGNED: The mean age of the elderly patients was 67±5.8 years, while the mean age of the younger patients was 49.2±10.9 years. Male predominance was lower in the older AS group compared to the younger AS group (p=0.002). During follow-up period, 397 patients (comprising 318 young and 79 elderly individuals) had a history of using at least one biological disease-modifying agent (bDMARD). There was no significant difference between the groups in terms of DMARD and bDMARD-use distributions. First tumor necrosis factor inhibitor (TNFi) retention rates were found to be similar in both groups over 10 years of follow-up. Adverse events were found to be similar in young (19.9%) and elderly (26.8%) AS patients.
UNASSIGNED: Research in the TURKBIO cohort reveals that both older and younger patients with AS exhibited similar disease activity levels with comparable treatment approaches. Moreover, the results of TNFi treatments in elderly patients were the same as those observed in younger patients, with no notable increase in safety concerns.
UNASSIGNED: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as <60 years of age (n=610), and those aged ≥60 years (n=201) were recorded as elderly patients. Demographic, clinical, and laboratory characteristics, along with disease activity markers and other follow-up parameters, as well as current and prior treatments, were electronically recorded during each visit using open-source software.
UNASSIGNED: The mean age of the elderly patients was 67±5.8 years, while the mean age of the younger patients was 49.2±10.9 years. Male predominance was lower in the older AS group compared to the younger AS group (p=0.002). During follow-up period, 397 patients (comprising 318 young and 79 elderly individuals) had a history of using at least one biological disease-modifying agent (bDMARD). There was no significant difference between the groups in terms of DMARD and bDMARD-use distributions. First tumor necrosis factor inhibitor (TNFi) retention rates were found to be similar in both groups over 10 years of follow-up. Adverse events were found to be similar in young (19.9%) and elderly (26.8%) AS patients.
UNASSIGNED: Research in the TURKBIO cohort reveals that both older and younger patients with AS exhibited similar disease activity levels with comparable treatment approaches. Moreover, the results of TNFi treatments in elderly patients were the same as those observed in younger patients, with no notable increase in safety concerns.
摘要：
■本研究旨在探讨年龄对强直性脊柱炎（AS）患者疾病活动性和生物治疗的影响。
■在2011年至2019年期间，共有811名在TURKBIO注册数据库中注册的AS患者根据进入注册时的年龄进行分类，并分配到以下两组中的一组：年轻患者，定义为<60岁(n=610)，年龄≥60岁（n=201）的患者被记录为老年患者。人口统计,临床,和实验室特点，以及疾病活动标记和其他随访参数，以及当前和先前的治疗方法，在每次访问期间使用开源软件进行电子记录。
■老年患者的平均年龄为67±5.8岁，而年轻患者的平均年龄为49.2±10.9岁。与年轻的AS组相比，老年AS组的男性优势较低（p=0.002）。在随访期间,397名患者（包括318名年轻人和79名老年人）有使用至少一种生物疾病调节剂（bDMARD）的病史。两组之间在DMARD和bDMARD使用分布方面没有显着差异。在10年的随访中，发现两组的第一肿瘤坏死因子抑制剂（TNFi）保留率相似。发现年轻（19.9％）和老年（26.8％）AS患者的不良事件相似。
■在TURKBIO队列中的研究表明，老年和年轻的AS患者在可比的治疗方法下表现出相似的疾病活动水平。此外，老年患者的TNFi治疗结果与年轻患者相同，安全问题没有明显增加。
■在2011年至2019年期间，共有811名在TURKBIO注册数据库中注册的AS患者根据进入注册时的年龄进行分类，并分配到以下两组中的一组：年轻患者，定义为<60岁(n=610)，年龄≥60岁（n=201）的患者被记录为老年患者。人口统计,临床,和实验室特点，以及疾病活动标记和其他随访参数，以及当前和先前的治疗方法，在每次访问期间使用开源软件进行电子记录。
■老年患者的平均年龄为67±5.8岁，而年轻患者的平均年龄为49.2±10.9岁。与年轻的AS组相比，老年AS组的男性优势较低（p=0.002）。在随访期间,397名患者（包括318名年轻人和79名老年人）有使用至少一种生物疾病调节剂（bDMARD）的病史。两组之间在DMARD和bDMARD使用分布方面没有显着差异。在10年的随访中，发现两组的第一肿瘤坏死因子抑制剂（TNFi）保留率相似。发现年轻（19.9％）和老年（26.8％）AS患者的不良事件相似。
■在TURKBIO队列中的研究表明，老年和年轻的AS患者在可比的治疗方法下表现出相似的疾病活动水平。此外，老年患者的TNFi治疗结果与年轻患者相同，安全问题没有明显增加。
